(0.21%) 5 142.25 points
(0.14%) 38 496 points
(0.33%) 17 905 points
(-0.16%) $83.72
(0.99%) $1.942
(0.21%) $2 352.20
(0.58%) $27.70
(1.86%) $939.25
(-0.16%) $0.933
(-0.24%) $11.00
(-0.27%) $0.798
(1.23%) $93.00
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 10.99%
@ $4.41
发出时间: 15 Feb 2024 @ 04:08
回报率: -12.47%
上一信号: Feb 15 - 03:15
上一信号:
回报率: -0.23 %
Live Chart Being Loaded With Signals
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America...
Stats | |
---|---|
今日成交量 | 1.39M |
平均成交量 | 2.13M |
市值 | 2.71B |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.0600 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.90 |
ATR14 | $0.00900 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Ronaghi Mostafa | Buy | 25 315 | Stock Option (right to buy) |
2024-04-11 | Ronaghi Mostafa | Buy | 200 000 | Stock Option (right to buy) |
2024-04-11 | Ronaghi Mostafa | Buy | 0 | |
2024-04-02 | Soni Manmeet Singh | Buy | 1 100 000 | Stock Option (right to buy) |
2024-04-02 | Anand Bhaskar | Buy | 600 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.43 |
Last 89 transactions |
Buy: 581 405 260 | Sell: 937 995 |
音量 相关性
Summit Therapeutics plc 相关性 - 货币/商品
Summit Therapeutics plc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-2.05M (0.00 %) |
EPS: | $-0.990 |
FY | 2023 |
营收: | $0 |
毛利润: | $-2.05M (0.00 %) |
EPS: | $-0.990 |
FY | 2022 |
营收: | $704 295 |
毛利润: | $-1.81M (-256.95 %) |
EPS: | $-0.380 |
FY | 2021 |
营收: | $1 809.00 |
毛利润: | $1 809.00 (100.00 %) |
EPS: | $-0.000960 |
Financial Reports:
No articles found.
Summit Therapeutics plc
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。